Atgal

Doc. dr. Vinco Urbono straipsniai

1. he impact of metformin on survival in patients with melanoma—national cohort study

Urbonas, V., Rutenberge, J., Patasius, A., ...Burokiene, N., Smailyte, G.

Annals of Epidemiology, 2020, 52, pp. 23–25

2. Response to Letter to the Editor: Metformin in colorectal cancer: A match ruled by MiR26b?

Linkeviciute-Ulinskiene, D., Dulskas, A., Patasius, A., ...Urbonas, V., Smailyte, G.

Cancer Epidemiology, 2020, 64, 101626

3. Positive effect of metformin treatment in colorectal cancer patients with type 2 diabetes: National cohort study

Dulskas, A., Dulskas, A., Dulskas, A., ...Smailyte, G., Smailyte, G.

European Journal of Cancer Prevention, 2020, pp. 289–293

4. Skin melanoma and subsequent risk of prostate cancer: A Lithuanian cancer registry study

Patasius, A., Urbonas, V., Smailyte, G.

International Journal of Environmental Research and Public Health, 2019, 16(20), 3915

5. Metformin increases cancer specific survival in colorectal cancer patients—National cohort study

Dulskas, A., Patasius, A., Linkeviciute-Ulinskiene, D., ...Urbonas, V., Smailyte, G.

Cancer Epidemiology, 2019, 62, 101587

6. Natural killer cell-based immunotherapy: A new fighter against melanoma?

Urbonas, V., Smailyte, G., Urbonaite, G.V., ...Burokiene, N., Kasiulevicius, V.

Melanoma Research, 2019, 29(2), pp. 208–211

7. Suicide risk among colorectal cancer patients in Lithuania

Dulskas, A., Patasius, A., Kaceniene, A., Urbonas, V., Smailyte, G.

International Journal of Colorectal Disease, 2019, 34(3), pp. 555–558

8. Breast Cancer Screening Program in Lithuania: Interval Cancers and Program Sensitivity After 7 Years of Mammography Screening

Steponaviciene, L., Vincerzevskiene, I., Briediene, R., ...Vanseviciute-Petkeviciene, R., Smailyte, G.

Cancer Control, 2019, 26(1)

9. Combination of cytokine-directed and anti-programmed cell death protein 1 therapy- A new attractive option in melanoma treatment?

Urbonas, V., Smailyte, G.

Melanoma Research, 2018, 28(5), pp. 469–470

10. The predictive value of soluble biomarkers (CD14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncology patients with chemotherapy-induced febrile neutropenia

Urbonas, V., Eidukaite, A., Tamuliene, I.

Cytokine, 2013, 62(1), pp. 34–37

11. The diagnostic value of interleukin-6 and interleukin-8 for early prediction of bacteremia and sepsis in children with febrile neutropenia and cancer

Urbonas, V., Eidukaite, A., Tamuliene, I.

Journal of Pediatric Hematology/Oncology, 2012, 34(2), pp. 122–127

12. Increased interleukin-10 levels correlate with bacteremia and sepsis in febrile neutropenia pediatric oncology patients

Urbonas, V., Eidukaitë, A., Tamulienë, I.

Cytokine, 2012, 57(3), pp. 313–315

13. Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.

Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P, Wheater M, Plummer E, Mauch C, Scudder C, Goff M, Love SB, Mohammed SB, Middleton MR.

Ann Oncol. 2019 Feb 1;30(2):317-324. doi: 10.1093/annonc/mdy500.PMID: 30428063 



Atnaujinta 2021-04-27 20:11

Mūsų svetainė naudoja slapukus (cookies). Šie slapukai skirti rinkti statistiką ir tobulinti svetainės veikimą bei parinkti tik Jums skirtą reklamą.

Jei Jūs sutinkate su šiems tikslams naudojamais slapukai, spauskite "sutinku" ir toliau naudokitės svetaine.

Sutinku
Nustatymai